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N euroendocrinological studies of patients with depression have focused on the hypothalamic- 
pituitary-adrenal (HPA) axis,  and depressed patients 
have been reported to have dysfunctional HPA axes [1].  
We and others have reported that the chronic adminis-
tration of adrenocorticotropic hormone (ACTH) for 14 
days to rats counteracted the effects of the tricyclic anti-
depressants imipramine and desipramine and decreased 
the amount of time the rats spent immobile in the 
forced swim test,  a behavioral test that is widely used as 
a predictor of antidepressive activity [2 , 3].  The chronic 
treatment of rats with ACTH might therefore represent 
an effective animal model of antidepressant treatment- 
resistant depression.
Ketamine is a non-competitive antagonist of the 
phencyclidine site of the N-methyl-D-aspartate (NMDA) 
receptor.  Clinically,  it is well known that ketamine 
exerts rapid and sustained antidepressive effects in 
depressed patients and treatment-resistant depressive 
patients [4-6].  In 2019,  the U.S.  Food and Drug 
Administration approved esketamine as a treatment for 
treatment-resistant depression.  It was reported that in 
rodents,  ketamine significantly decreased immobility in 
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Ketamine has been clinically proven to ameliorate depression,  including treatment-resistant depression.  The 
detailed mechanism of action of ketamine in treatment-resistant depression remains unclear.  We examined the 
effects of ketamine on the immobility times of adrenocorticotropic hormone (ACTH)-treated rats during the 
forced swim test,  and we explored the mechanism by which ketamine acts in this model.  We investigated the 
neuroanatomical site of action by microinjecting ketamine into the medial prefrontal cortex of rats.  A signifi-
cant reduction of the rats’ immobility during the forced swim test was observed after the intraperitoneal injec-
tion of ketamine in both saline- and ACTH-treated rats.  The microinjection of ketamine into the medial pre-
frontal cortex also decreased immobility during the forced swim test in both saline- and ACTH-treated rats.  
The immobility-decreasing effect of intraperitoneally injected ketamine was blocked by administering 
WAY100635,  a 5-HT1A receptor antagonist,  into the medial prefrontal cortex.  These findings contribute to the 
evidence that ketamine can be useful against treatment-resistant depressive conditions.  The immobility-reduc-
ing effects of ketamine might be mediated by 5-HT1A receptor activity in the medial prefrontal cortex.
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the forced swim test [7 , 8],  and that ketamine signifi-
cantly decreased the amount of time ACTH-treated rats 
spent immobile during the forced swim test [3].  These 
results suggested that ketamine could be effective 
against antidepressant treatment-resistant depression.
The serotonin (5-HT)1A receptor has been implicated 
in the pathophysiology of major depressive disorder in 
both animal models and humans [9 , 10].  We observed 
that the 5-HT1A receptor full agonist (±)-8-hydroxy-2-
(di-n-propylamino)tetralin significantly reduced the 
amount of time saline- and ACTH-treated rats spent 
immobile during the forced swim test [11].  Thus,  the 
5-HT1A receptor might play an important role in 
depression,  particularly in depression that is resistant to 
tricyclic antidepressant treatment.  The antidepressive 
effects of ketamine might also be mediated by post-syn-
aptic 5-HT1A receptor activity in mice [12].  In mice that 
underwent the novelty-suppressed feeding test,  the 
antidepressive effects of ketamine were attenuated by 
WAY100635,  a 5-HT1A receptor antagonist,  but not 
ritanserin,  a 5-HT2A/2C receptor antagonist [13].  These 
findings suggested that ketamine exerts its effects by 
indirectly activating postsynaptic 5-HT1A receptors.  
Ketamine might therefore be effective in animal models 
of depressive conditions that are resistant to tricyclic 
antidepressant treatment,  and these effects might be 
mediated by post-synaptic 5-HT1A receptor activity.
The role of the medial prefrontal cortex (MPC) in 
depression has been extensively studied.  Conditioned 
fear stress selectively increased 5-HT metabolism in the 
MPC [14].  Ketamine increased the release of 5-HT 
from the MPC,  probably by activating neurons in the 
dorsal raphe nucleus [15 , 16].  Following its microinjec-
tion into the MPC of rodents,  ketamine was observed to 
exert antidepressive effects in the forced swim test,  and 
these effects were attenuated by depleting 5-HT using 
p-chlorophenylalanine,  an inhibitor of 5-HT synthesis 
[17].  These findings suggested that the MPC serotoner-
gic system is deeply involved in the psychopathology of 
depression and anxiety.
We conducted the present study to investigate 
whether ketamine treatment would reduce the amount 
of time ACTH-treated rats spent immobile during the 
forced swim test.  To explore the role of the 5-HT1A 
receptor in the antidepressant-like effects of ketamine,  
we also examined whether the effects of ketamine are 
mediated via 5-HT1A receptors in the MPC.
Materials and Methods
Animals. Wistar rats (Charles River,  Yokohama,  
Japan) with initial weights of 210-230 g were used.  The 
rats were housed 2 per cage in an air-conditioned room 
(23 ± 1°C; approximate humidity level: 60%) under a 
constant light-dark cycle (lights on: 7 : 00 a.m.  to 
7 : 00 p.m.) and were fed standard laboratory food and 
tap water.  All experiments were conducted according to 
the guidelines for animal experimentation at Okayama 
University Medical School.  All efforts were made to 
minimize the number of animals used and the degree of 
suffering they experienced.
Drug administration. The following drugs were 
used: ketamine (Ketalar®; Daiichi-Sankyo,  Tokyo),  
WAY100635 (Sigma-Aldrich,  St. Louis,  MO,  USA),  
and ACTH-(1-24)-zinc (Cortrosyn Z; Daiichi-Sankyo).  
The rats were administered ketamine intraperitoneally 
at a dose of 2 ml/kg body weight.  ACTH was injected 
subcutaneously once daily (at 9 : 00-10 : 00 a.m.) for 14 
days at a dose of 100 μg/rat (injection volume: 0.2 ml/
rat).  The control rats received an equivalent volume of 
vehicle (saline,  0.2 ml/rat,  subcutaneously injected) for 
the same period of time.  The amount of time the con-
trol rats spent immobile was assessed 60 min after the 
administration of a single dose of ketamine (10-20 mg/
kg,  i.p.) to rats that had been treated with ACTH for 14 
days.  The last injection of ACTH was given immedi-
ately after the pre-swim test.  Ketamine was adminis-
tered the next day,  without concurrent ACTH treat-
ment.  The amount of time the rats spent immobile was 
assessed 60 min after the administration of ketamine as 
described below.
Microinjections. Rats were anesthetized by a sin-
gle intraperitoneal administration of sodium pentobar-
bital (50 mg/kg) and were fixed to a brain stereotactic 
apparatus (Narishige,  Tokyo).  For the injection of ket-
amine into the MPC,  the rat’s brain was implanted with 
bilateral guide cannulas (AG-8; Eicom,  Kyoto,  Japan),  
and the tips were positioned in the MPC (anteroposte-
rior: + 3.2 mm in front of the bregma suture,  midline:  
± 0.6 mm,  dorsoventral: − 3.2 mm,  angle: 20°).  The 
cannulas were held in place with dental cement.  A 
dummy cannula was inserted into the guide cannula to 
prevent clogging.
The microinjection of ketamine or WAY100635 was 
performed on day 2 after surgery.  The injection cannula 
(AMI-8; Eicom Co.,  Kyoto,  Japan) was connected via 
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Teflon tubing to a Hamilton microsyringe driven by a 
microinfusion pump (CMA/100 syringe pump; Carne-
gie Medicine,  Stockholm,  Sweden).  The injections 
were performed for 1 min at a rate of 1 µl/min.  The 
injection cannulas were left in position for an additional 
1 min before being withdrawn.  After the behavioral 
test,  Evans blue dye was infused and then coronal sec-
tions were prepared to confirm the locations of the can-
nula tips.  The ketamine and WAY100635 were diluted 
with Ringer’s solution prior to being used for the MPC 
microinjections.
Assessment of immobility. For the assessment of 
immobility,  individual rats were placed in plastic cylin-
ders (height 37 cm,  dia. 15.5 cm),  containing 20 cm of 
water at 25°C,  as described by Porsolt et al.  [18].  Two 
swimming sessions were conducted in the initial 
13-min pretest,  and a 6-min test was performed 24 h 
later.  The total amount of time each rat spent immobile 
during the 6-min test period was recorded by a TARGET 
series/7M analysis program (Neuroscience Inc.,  Tokyo).
On the 15th day of treatment,  immobility was 
assessed 60 min after the administration of a single 
dose of ketamine (10-20 mg/kg,  i.p.) without ACTH.  In 
the microinjection experiments,  immobility was 
assessed 15 min after the microinjection of ketamine 
(1-15 µg/side) into the MPC without ACTH on the 
15th day of treatment.  In the experiment involving the 
microinjection of WAY100635,  WAY100635 (1 nmol/
side) was administered 20 min before the assessment of 
mobility.
Locomotor activity. The rats’ locomotor activity 
was monitored for 6 min with the use of automated 
activity monitoring chambers (Neuroscience,  Inc.).  The 
plastic chambers measured 23 cm (width) by 40 cm 
(length) by 18 cm (height).
Statistical analyses. All data are expressed as 
mean±standard error of the mean (SEM) values.  The 
immobility time and locomotor activity were analyzed 
by a one-way analysis of variance (ANOVA).  The group 
means were compared using Dunnett’s test (Figs. 1 , 2;  
Table 1) and Tukey’s test (Fig. 3) for multiple compari-
sons.  For the evaluation of the influence of the ket-
amine injection into the MPC on the rats’ locomotor 
activity,  comparisons between the 2 groups were per-
formed using the unpaired two-tailed Student’s t-test.  
P-values of < 0.05 were considered significant.
Results
Effects of ketamine on immobility in saline- and 
ACTH-treated rats. We examined the amount of 
time that the saline- and ACTH-treated rats spent 
immobile during the forced swim test after they were 
treated with ketamine (10-20 mg/kg,  i.p.).  Ketamine 
significantly reduced the amount of time spent immo-
bile during the forced swim test in both the saline- and 
ACTH-treated rats (control: F(3 , 20) = 7.31,  p < 0.01;  
ACTH: F(3 , 20) = 3.11,  p < 0.05) (Fig. 1).
Effects of the infusion of ketamine into the MPC on 





































Control 10 15 20
Ketamine (mg/kg, i.p.)
???? ?　 The effects of ketamine on the amount of time saline- or ACTH-treated rats spent immobile during the forced swim test.  
Immobility was assessed 60 min after the administration of ketamine (10-20 mg/kg,  i.p.) in saline- and ACTH-treated rats.  We repeatedly 
administered ACTH (100 μg/day,  s.c.,  14 days) to rats for 14 days.  On the 15th day,  ketamine was administered without ACTH.  Each 
column represents the mean±SEM (n=6 for each group).  Data were analyzed with a one-way ANOVA,  and group means were compared 
using Dunnettʼs test for multiple comparisons.  ＊P<0.05 vs. the control group.  ＊＊P<0.01 vs. the control group.
spent immobile. We examined the effects of ket-
amine (1-10 μg/side) injected into the MPC on the 
amount of time saline- and ACTH-treated rats spent 
immobile during the forced swim test (Fig. 2).  The infu-
sion of 10 μg/side ketamine into the MPC decreased the 
amount of time the control rats spent immobile during 
the forced swim test (F(3 , 15)= 8.77,  p< 0.01).  Similarly,  
the infusion of 15 μg/side ketamine into the MPC sig-
nificantly decreased the amount of time the ACTH-
treated rats spent immobile during the forced swim test 
(F(2 , 11) = 4.48,  p < 0.05) (Fig. 2).
Effects of ketamine on locomotor activity in saline- 
and ACTH-treated rats. Ketamine (20 mg/kg,  i.p.) 
significantly decreased the locomotor activity of the 
saline- and ACTH-treated rats (saline: F(3 , 20) = 0.001,  
p < 0.01; ACTH: F(3 , 20) = 3.13,  p < 0.05) (Table 1).  In 
contrast,  the injection of 10 or 15 µg/side ketamine into 
the MPC did not affect locomotor activity in the saline- 
or ACTH-treated rats (Table 2).
Effects of the microinjection of WAY100635 into the 
MPC on the immobility-decreasing effects of ketamine 
in the forced swim test. The effects of the microin-
jection of WAY100635 into the MPC on the ketamine- 
induced reduction of time the rats spent immobile 
during the forced swim test are illustrated in Fig. 3.  The 
reduction in immobility induced by ketamine (20 mg/
kg,  i.p.) was prevented by microinjecting WAY100635 
(1 nmol/side) into the MPC (F(3 , 39) = 3.71,  p < 0.05).
Discussion
Our findings clarify the effects of an intraperitoneal 
injection of ketamine and a microinjection of ketamine 
into the MPC on the amount of time ACTH-treated rats 
spent immobile during the forced swim test.  The 
observed effects of ketamine (i.p.) agree with the results 
obtained for normal and ACTH-treated rats in previous 
studies [3 , 12].
In a study using mice,  the microinjection of ket-
amine into the MPC decreased immobility [16 , 17],  and 
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ACTH (100 g/rat,  s.c.) was administered to the rats once daily for 
14 days.  Locomotor activity was measured on the day after the final 
dose of ACTH was administered,  60 min after the ketamine injec-
tion.  Data are mean±SEM values (n=5-6 rats).  The data were 
analyzed with a one-way ANOVA,  and group means were compared 







































???? ?　 The effects of the microinjection of ketamine into the MPC for 14 days on the amount of time saline- or ACTH-treated rats spent 
immobile during the forced swim test.  We examined the effects of injecting a single dose of ketamine (1-15 μg/side) into the MPC on the 
amount of time rats spent immobile during the forced swim test.  Immobility was assessed 15 min after the administration of ketamine.  We 
repeatedly administered ACTH (100 μg/day,  s.c.,  14 days) to rats for 14 days.  On the 15th day,  ketamine was administered without 
ACTH.  Each column represents the mean±SEM (n=4-6,  each group).  Data were analyzed with a one-way ANOVA,  and group means 
were compared using Dunnettʼs test for multiple comparisons.  ＊P<0.05,  ＊＊P<0.01 vs. the control group.
in the present investigation using rats,  the infusion of 
ketamine at a dose of 10 μg/side into the MPC signifi-
cantly reduced the amount of time the control rats spent 
immobile during the forced swim test.  In the ACTH-
treated rats,  the infusion of ketamine at 15 μg/side into 
the MPC significantly reduced the amount of time they 
spent immobile during the forced swim test.  Taken 
together,  the previous and present results suggest that 
ketamine may improve the  antidepressant treatment- 
resistant depression.
To determine whether the observed changes in 
immobility were associated with reductions in locomo-
tor activity,  we examined the effects of ketamine on 
locomotor activity in saline- and ACTH-treated rats.  
Only the highest dose of ketamine (20 mg/kg,  i.p.) 
decreased the locomotor activity of both the saline- and 
ACTH-treated rats.  It is therefore unlikely that the ten-
dency for ketamine to reduce immobility in the forced 
swim test was related to the drug’s effect on locomotor 
activity.
In mice,  the antidepressive effects of ketamine 
appear to be mediated by 5-HT1A receptor activity in the 
MPC [12].  We reported the effects of 8-OH-DPAT,  a 
5-HT1A receptor agonist,  on the immobility exhibited 
by saline- or ACTH-treated rats during the forced swim 
test [11],  and we observed that 8-OH-DPAT potently 
reduced the amount of time the ACTH-treated rats 
spent immobile during the forced swim test,  in a dose- 
dependent manner.  This suggests that the 5-HT1A 
receptor plays an important role in depression,  particu-
larly in depression that is resistant to tricyclic antide-
pressant treatment.  We also observed that the microin-
jection of WAY100635 (a 5-HT1A receptor antagonist) 
into the MPC blocked the immobility-decreasing effects 
of ketamine.  The present results thus indicate that the 
stimulation of 5-HT1A receptors in the MPC might play 
an important role in the antidepressive effects of ket-
amine.
It was reported that the sustained antidepressant- 
like effects of ketamine increase the release of 5-HT in 
the MPC through local mechanisms,  such as inhibition 
of the 5-HT transporter,  or through the activation of 
the dorsal raphe nucleus neurons by MPC projection 
[12].  A recent study concerning 5-HT1A receptor func-
tion revealed that the antidepressant-like effects of ket-
amine are mediated by the post-synaptic 5-HT1A recep-
tor and the subsequent activation of phosphoinositide-3 
kinase/Akt/mechanistic target of rapamycin complex-1 
(PI3K/Akt/mTORC1) signaling in the MPC [19].  
Ketamine is a non-competitive NMDA receptor antag-
onist.  In the glutamatergic system,  the metabotropic 
glutamate (mGlu) receptors are known to have modula-
tory roles in glutamatergic transmission,  and their roles 
in depression have been investigated [20].  Importantly,  
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????? ?　 Influence of the infusion of ketamine into the medial 
prefrontal cortex (MPC) on locomotor activity in saline- and ACTH-
treated rats
a) Saline
Treatment Locomotor activity (counts)
Saline 165.0±12.2
Ketamine (10 μg/side) 181.2±15.0
b) ACTH
Treatment Locomotor activity (counts)
ACTH 201.5±9.3
ACTH+ketamine (15 μg/side) 189.0±12.3
ACTH (100 g/rat,  s.c.) was administered to the rats once daily for 
14 days.  Locomotor activity was measured on the day after the final 
dose of ACTH was administered,  15 min after the infusion of ket-
amine into the MPC.  Data are expressed as the mean±SEM val-






















???? ?　 The effects of microinjecting WAY100635 into the MPC 
on the immobility-reducing effects of ketamine in rats during the 
forced swim test.  Immobility was assessed 60 min after the admin-
istration of ketamine (20 mg/kg,  i.p.).  WAY100635 (1 nmol/side) 
was injected into the MPC 20 min before the examination.  Each 
column represents the mean±SEM (n=9-12,  each group).  Data 
were analyzed with a one-way ANOVA,  and group means were 
compared using Tukeyʼs test for multiple comparisons.  ＊P<0.05 
vs. the control group.
an mGlu2/3 receptor antagonist had rapid and 
long-lasting ketamine-like antidepressive effects on 
treatment-resistant depression in rodents [19 , 21-23].  
Further studies are in progress to clarify the detailed 
mechanisms underlying the effects of ketamine in 
ACTH-treated rats.
In conclusion,  the present results demonstrated that 
ketamine exerted antidepressant-like effects via the 
medial prefrontal cortex in both control and ACTH-
treated rats.  Ketamine might have important effects on 
depression that are mediated through 5-HT1A receptors 
in the medial prefrontal cortex.
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